Weinberg Uri Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
7
Insider Sells Sum
$4.03M

Insider Activity of Weinberg Uri

According to the SEC Form 4 filings, Weinberg Uri, being in a position of

  1. Chf Medical and Innovation Ofr at Novocure Ltd,
    оver the last 12 months, has bought 0 shares, and sold 17145 shares for $232,178,
    over all time since 2020-09-25, has bought 0 shares, and sold 49299 shares for $4.27M.

Biography of Weinberg Uri

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $232,1783100

Comparison of Insiders on Amount of Buys and Sells

2026-03-04SaleNovoCure Limited
NVCR
Chf Medical and Innovation Ofr
6,412
0.0057%
$13.31$85,314+18.03%
2026-03-02SaleNovoCure Limited
NVCR
Chf Medical and Innovation Ofr
3,272
0.0028%
$13.33$43,607+17.09%
2026-02-27SaleNovoCure Limited
NVCR
Chf Medical and Innovation Ofr
7,461
0.0067%
$13.84$103,257+15.76%
2025-03-03SaleNovoCure Limited
NVCR
Chief Innovation Officer
268
0.0003%
$18.92$5,071-25.8%
2025-02-28SaleNovoCure Limited
NVCR
Chief Innovation Officer
4,637
0.0042%
$18.75$86,949-28.11%
2023-01-05SaleNovoCure Limited
NVCR
Chief Science Officer
5,764
0.0053%
$114.55$660,276-65.88%
2021-05-10SaleNovoCure Limited
NVCR
Chief Science Officer
5,650
0.0057%
$189.65$1.07M-40.68%
2021-03-23SaleNovoCure Limited
NVCR
Chief Science Officer
2,835
0.0028%
$140.00$396,900-9.66%
2021-02-22SaleNovoCure Limited
NVCR
Chief Science Officer
6,500
0.0061%
$175.50$1.14M-27.19%
2020-09-25SaleNovoCure Limited
NVCR
Chief Science Officer
6,500
0.0062%
$103.35$671,775+47.32%
Total: 10
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.